You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Product Overview

Combodart is indicated for the management of moderate to severe symptomatic benign prostatic hyperplasia (BPH).

Drug-disease modelling: BPH Webinar 25th September 2019

ELITE Webcast


The impact of early vs delayed initiation of combination therapy for BPH medical management

Watch expert discussion on clinical management now.

Combodart is a registered trademark of the GlaxoSmithKline group of companies